MC2 Therapeutics launches psoriasis cream in US

The pharmaceutical firm has worked with partner Epi Health to launch Wynzora on the US market, where it was authorized as a treatment for psoriasis last year.

Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics/PR

Just under a year after MC2 Therapeutics received approval from the FDA for its psoriasis cream Wynzora, the treatment has been launched on the US market, the company reports in a press release.

The launch has been planned in collaboration with partner Epi Health, which specializes in dermatology, though MC2 has been working to establish itself as an independent company in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs